Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice

Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Kenji Kuroda, Mototsugu Oya, Takashi Ohigashi, Nozomu Takahashi, Yutaka Shima, Kazuo Umezawa, Masaru Murai

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

We have synthesized and explored the feasibility of using a novel nuclear factor (NF) κB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. The activity of NFκB, evaluated by transient transfection of a luciferase reporter DNA containing a specific binding sequence for NFκB, was inhibited by DHMEQ in three human hormone-refractory prostate cancer cell lines, DU145, JCA-1, and PC-3. Statistically significant growth inhibition was achieved by 20 μg/ml of DHMEQ, and marked levels of apoptosis were induced 48 h after DHMEQ administration in vitro. Electrophoretic mobility shift assay showed that DHMEQ completely inhibited NFκB DNA binding activity in JCA-1 cells. Furthermore, i.p. administrations of DHMEQ significantly inhibited pre-established JCA-1 s.c. tumor growth in nude mice without any side effects. Our result indicates the possibility of using a novel NFκB activation inhibitor, DHMEQ, as a new treatment strategy against hormone-refractory prostate cancer.

Original languageEnglish
Pages (from-to)107-110
Number of pages4
JournalCancer Research
Volume63
Issue number1
Publication statusPublished - 2003 Jan 1

Fingerprint

Nude Mice
Prostatic Neoplasms
Hormones
DNA
Electrophoretic Mobility Shift Assay
Growth
Luciferases
Transfection
Apoptosis
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kikuchi, E., Horiguchi, Y., Nakashima, J., Kuroda, K., Oya, M., Ohigashi, T., ... Murai, M. (2003). Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Research, 63(1), 107-110.

Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. / Kikuchi, Eiji; Horiguchi, Yutaka; Nakashima, Jun; Kuroda, Kenji; Oya, Mototsugu; Ohigashi, Takashi; Takahashi, Nozomu; Shima, Yutaka; Umezawa, Kazuo; Murai, Masaru.

In: Cancer Research, Vol. 63, No. 1, 01.01.2003, p. 107-110.

Research output: Contribution to journalArticle

Kikuchi, E, Horiguchi, Y, Nakashima, J, Kuroda, K, Oya, M, Ohigashi, T, Takahashi, N, Shima, Y, Umezawa, K & Murai, M 2003, 'Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice', Cancer Research, vol. 63, no. 1, pp. 107-110.
Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Research. 2003 Jan 1;63(1):107-110.
Kikuchi, Eiji ; Horiguchi, Yutaka ; Nakashima, Jun ; Kuroda, Kenji ; Oya, Mototsugu ; Ohigashi, Takashi ; Takahashi, Nozomu ; Shima, Yutaka ; Umezawa, Kazuo ; Murai, Masaru. / Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. In: Cancer Research. 2003 ; Vol. 63, No. 1. pp. 107-110.
@article{f1d3a3051c10427d9f4855851c6645d2,
title = "Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice",
abstract = "We have synthesized and explored the feasibility of using a novel nuclear factor (NF) κB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. The activity of NFκB, evaluated by transient transfection of a luciferase reporter DNA containing a specific binding sequence for NFκB, was inhibited by DHMEQ in three human hormone-refractory prostate cancer cell lines, DU145, JCA-1, and PC-3. Statistically significant growth inhibition was achieved by 20 μg/ml of DHMEQ, and marked levels of apoptosis were induced 48 h after DHMEQ administration in vitro. Electrophoretic mobility shift assay showed that DHMEQ completely inhibited NFκB DNA binding activity in JCA-1 cells. Furthermore, i.p. administrations of DHMEQ significantly inhibited pre-established JCA-1 s.c. tumor growth in nude mice without any side effects. Our result indicates the possibility of using a novel NFκB activation inhibitor, DHMEQ, as a new treatment strategy against hormone-refractory prostate cancer.",
author = "Eiji Kikuchi and Yutaka Horiguchi and Jun Nakashima and Kenji Kuroda and Mototsugu Oya and Takashi Ohigashi and Nozomu Takahashi and Yutaka Shima and Kazuo Umezawa and Masaru Murai",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "63",
pages = "107--110",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice

AU - Kikuchi, Eiji

AU - Horiguchi, Yutaka

AU - Nakashima, Jun

AU - Kuroda, Kenji

AU - Oya, Mototsugu

AU - Ohigashi, Takashi

AU - Takahashi, Nozomu

AU - Shima, Yutaka

AU - Umezawa, Kazuo

AU - Murai, Masaru

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We have synthesized and explored the feasibility of using a novel nuclear factor (NF) κB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. The activity of NFκB, evaluated by transient transfection of a luciferase reporter DNA containing a specific binding sequence for NFκB, was inhibited by DHMEQ in three human hormone-refractory prostate cancer cell lines, DU145, JCA-1, and PC-3. Statistically significant growth inhibition was achieved by 20 μg/ml of DHMEQ, and marked levels of apoptosis were induced 48 h after DHMEQ administration in vitro. Electrophoretic mobility shift assay showed that DHMEQ completely inhibited NFκB DNA binding activity in JCA-1 cells. Furthermore, i.p. administrations of DHMEQ significantly inhibited pre-established JCA-1 s.c. tumor growth in nude mice without any side effects. Our result indicates the possibility of using a novel NFκB activation inhibitor, DHMEQ, as a new treatment strategy against hormone-refractory prostate cancer.

AB - We have synthesized and explored the feasibility of using a novel nuclear factor (NF) κB inhibitor, a dehydroxymethylepoxyquinomicin designated as DHMEQ, against prostate cancer. The activity of NFκB, evaluated by transient transfection of a luciferase reporter DNA containing a specific binding sequence for NFκB, was inhibited by DHMEQ in three human hormone-refractory prostate cancer cell lines, DU145, JCA-1, and PC-3. Statistically significant growth inhibition was achieved by 20 μg/ml of DHMEQ, and marked levels of apoptosis were induced 48 h after DHMEQ administration in vitro. Electrophoretic mobility shift assay showed that DHMEQ completely inhibited NFκB DNA binding activity in JCA-1 cells. Furthermore, i.p. administrations of DHMEQ significantly inhibited pre-established JCA-1 s.c. tumor growth in nude mice without any side effects. Our result indicates the possibility of using a novel NFκB activation inhibitor, DHMEQ, as a new treatment strategy against hormone-refractory prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037227989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037227989&partnerID=8YFLogxK

M3 - Article

C2 - 12517785

AN - SCOPUS:0037227989

VL - 63

SP - 107

EP - 110

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -